Tests promise blockbuster new heart attack drug The Nation
WASHINGTON - An experimental drug from Swiss pharma giant Novartis reduced deaths from chronic heart failure by 20 percent compared with an existing treatment, according to the results of a vast new study. The new drug, called LCZ696, has been ...
WASHINGTON - An experimental drug from Swiss pharma giant Novartis reduced deaths from chronic heart failure by 20 percent compared with an existing treatment, according to the results of a vast new study. The new drug, called LCZ696, has been ...